Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.09 · Revenue $951.79M · 1 analysts
Est. EPS $0.18 · Revenue $3.69B · 4 analysts
Est. EPS $0.26 · Revenue $979.90M · 1 analysts
Est. EPS $0.47 · Revenue $1.06B · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $3.2B | +17.7% | +3.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-207.9M | +79.8% | -338.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +69.7% | +0.2% | +2.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -3.1% | +92.0% | -190.7% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -6.4% | +82.8% | -324.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $356.8M | +378.6% | -36.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +11.0% | +306.7% | -38.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 105.1% | -8.4% | +3.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.43x | +13.1% | -18.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $5.9B | -1.1% | -0.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.10 vs -0.70 | -57.5% | -0.45 vs 0.09 | -586.5% |
| Revenue Surprise | $3.2B vs $3.2B | +0.5% | $878.4M vs $951.8M | -7.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Baranick Brian | officer: EVP, GM, Precision Oncology | Common Stock | A | 33,321 | — |
| Mar 23, 2026 | Baranick Brian | officer: EVP, GM, Precision Oncology | Common Stock | D | 795 | — |
| Mar 23, 2026 | Baranick Brian | officer: EVP, GM, Precision Oncology | Restricted Stock Units | D | 28,063 | — |
| Mar 23, 2026 | Herriott James | officer: SVP, General Counsel & Sec | Common Stock | D | 1,762 | $0.01 |
| Mar 23, 2026 | Herriott James | officer: SVP, General Counsel & Sec | Stock Options (Right to Buy) | D | 793 | $92.62 |
Operator: Hello, and welcome to the Exact Sciences Third Quarter 2025 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Derek Leckow. You may begin. Derek Leckow: Thank you for joining us for Exact Sciences' Third Quarter 2025 Conference Call today, November 3, 2025. On the call today are Kevin Conroy, the company's Chairman and CEO; and Aaron Bloomer, our Chief Financial Officer. Earlier this afternoon, Exact Sciences issued a news release detailing our third quarter financial results. This news release and today's presentation are available on our website at exactsciences.com. During today's call, we will make forward-looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are included in our earnings press release, and descriptions of the risks and uncertainties associated with Exact Sciences are included in our SEC filings. Both can be accessed through our website. I will now turn the call over to Kevin. Kevin Conroy: Thanks, Derek. The Exact Sciences team delivered record results in the third quarter. Thanks to the team's execution, we're raising our full year 2025 revenue and adjusted EBITDA guidance. A few highlights from the quarter include growing revenue 20% to $851 million, the highest quarterly growth rate in over 2 years. This was driven by Cologuard's strong brand awareness, inspiring commercial execution, accelerating health systems integrations and a record number of ordering providers. Screening 0.25 million more people in the third quarter versus last year, deepening our relationships with payers and health systems by helping close gaps in guideline recommended cancer screening and launching Cancerguard, our multi-cancer early detection test. Our team is focused on continued commercial effectiveness, expanding access to Cologuard Plus, and driving adoption of our new tests to close a strong year. I will now pass the call to Aaron to discuss our financial results. Aaron Bloomer: Thanks, Kevin, and good afternoon, everyone. Total revenue grew 20% year-over-year to $851 million, $43 million above the midpoint of our guidance. Growth was led by screening, which increased 22% year-over-year to $666 million. We saw broad-based Cologuard growth led by strong execution from the commercial organization, care gap programs and rescreens. Precision Oncology revenue increased 12% year-over-year on a core basis to $183 million. Growth was led by continued Oncotype DX expansion internationally, U.S. Oncotype DX volumes and partner revenues. We generated $135 million in adjusted EBITDA, an increase of $37 million or 37% year-over-year. Adjusted EBITDA margins expanded 200 basis points to 16%, driven by continued efficiency efforts across our lab, supply chain, G&A and support functions. Non-GAAP gross margins were 71%, down 100 basis points versus last year. The reduction was …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Kevin T. Conroy | Chairman of the Board, President & CEO | USD 28,273,855 | Male | 1966 | Active |
Brian Baranick | Executive Vice President & General Manager of Precision Oncology | USD 8,166,465 | Male | 1979 | Active |
Jacob Orville | Executive Vice President & GM of Screening | USD 7,331,065 | Male | 1974 | Active |
Sarah Condella | Executive Vice President of Human Resources & Service | USD 4,827,820 | Female | 1982 | Active |
Aaron Bloomer | EVP & CFO | USD 3,537,500 | Male | 1987 | Active |
Graham Lidgard | Emeritus Chief Science Officer | USD 937,039 | Male | 1949 | Active |
James Herriott | Senior Vice President, General Counsel & Secretary | — | Male | 1981 | Active |
Nassar Nizami | Chief Information Officer | — | Male | — | Active |
Derek Leckow | Vice President of Investor Relations | — | — | — | Active |
Jorge A. Garces | Chief Science Officer | — | — | 1972 | Active |
Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
